Latest News
-
1:10 Split, Rs 51 Dividend: Accumulate Tata Stock, TP Rs 170; Big Update On £1.25 Bn Investment -
Tech Mahindra Sets Three-Year Plan for Robust Growth and Market Leadership by FY27 -
Tech Mahindra Q4 Net Profit Falls 41%, Announces Growth Strategy -
3 Bonus, 1:2 Split, 38 Dividends: Rs 1,915 Midcap IT Stock To Pay 360% Dividend After Q4 Profit Rises -
EU Finds No New ETO Cases in Indian Organic Exports Post-Dec 2020 -
1:5 Stock Split Approved: Defence Stock To Be Cheaper Soon, Shares Zoom 507% In 1-Yr -
Edelweiss Alternatives Expands Portfolio with Bengaluru's MMTP Projects Acquisition -
1:2 Split, 1:1 Bonus, Rs 28/Sh Dividend: Mahindra's IT Stock To Pay 560% Dividend; Check Record, Payment Dates -
Kotak Mahindra Bank Takes Steps to Address RBI's IT Compliance Issues -
IndiGo to Expand Fleet with Up to 100 Airbus A350 Wide-Body Aircraft
For Daily Alerts
Shares in Natco Rally On Hepatitis Approval
Shares in Natco rallied after the company received an approval for generic Hepatitis C medicine. The stock was up over 5 per cent at Rs 1,963 on the National Stock Exchange.
"Natco Pharma is pleased to announce that it is the 1st company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India)," the company said in a press release.
GoodReturns.in
Story first published: Thursday, March 12, 2015, 12:20 [IST]
